that have already begun human testing. Slaoui’s financial stake in Moderna threatened to sway his decisions on the task force to benefit his own financial interest, rather than the public interest.
When Slaoui was introduced by Trump on Friday, he said the president’s aim to develop a vaccine by the end of the year was “credible,” but “extremely challenging.” He referred to positive results from a clinical study ― likely Moderna’s, but he did not name the company. NEW: Pres. Trump appoints former pharmaceutical executive Moncef Slaoui and Army Gen. Gustave Perna to lead vaccine development.
The two struck notes of optimism about the hoped-for pace of development, while conceding it will be a "herculean task."
Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше: